We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug News
Trending
Commercial Operations
GMPs, Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews Drug Daily Bulletin
Drug Industry Daily
Device News
Trending
Commercial Operations
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews Device Daily Bulletin
FDAnews Device Daily Bulletin Premium
Books
FDAnews Books Library
Drug Books
Device Books
Training/Events
Webinar Training Pass
Events
Resources
Form 483s Database
FDA Approved Drugs
eCFR and Guidances
White Papers
CenterWatch
About Us
The Company
Contact Us
Advertising
Sign In
Create Account
Sign Out
My Account
Home
» Hudson Scientific Falls Short on Process Controls
Hudson Scientific Falls Short on Process Controls
August 31, 2020
Devices
Inspections and Audits
Process control procedures were found to be lax during an FDA inspection of Hudson Scientific’s Hudson, Michigan facility.
To View This Article:
Login
Email
Password
Register
Remember Me
Forgot your password?
Subscribe To International Devices & Diagnostics Monitor
Upcoming Events
04
Apr
Optimizing Quality Control Operations with Unified Quality
20
Apr
Medical Device Enforcement: Latest Developments from the FDA, DOJ and FTC
25
Apr
Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials
26
Apr
FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know
27
Apr
Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis
17
May
2023 WCG Avoca Quality Consortium Summit
Featured Products
FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485
Selecting and Implementing Electronic Document Management Systems in the EU
Featured Stories
GrayMatters Health’s Digital Therapy Device for PTSD Cleared
Dupixent Shows Positive Results in COPD Study
Advamedica’s Hemostat Cleared for Severe Surgical Bleeding
FDA Approves Sandoz’s Citrate-Free Adalimubab Formulation
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More
